MCL Literature Feed

Brexucabtagene autoleucel (CAR-T) combined with BTK inhibitors is a potentially safe and effective strategy for treating relapsed mantle cell lymphoma with central nervous system involvement.

Combining CAR-T therapy with a BTK inhibitor may offer a synergistic strategy to effectively treat mantle cell lymphoma with central nervous system involvement, a historically poor-prognosis population.

An indirect comparison suggests brexucabtagene autoleucel provides superior response rates and progression-free survival over pirtobrutinib for MCL patients who have failed a prior covalent BTKi.

This review provides a framework for integrating bispecific antibodies into MCL treatment, addressing the critical clinical question of how to sequence them with other novel immunotherapies like CAR-T.

The EHA/EBMT ICAHT grading system better predicts severe infections and mortality post-CAR-T than CTCAE, which is highly relevant as MCL patients showed the highest rates of severe hematotoxicity.

The CAR-T therapy lisocabtagene maraleucel demonstrates high, durable complete responses and a favorable safety profile in heavily pretreated, relapsed/refractory MCL, including high-risk patients.

This article summarizes Israeli national guidelines for administering CAR-T therapy in relapsed/refractory MCL, detailing patient management, toxicity monitoring for CRS and ICANS, and long-term follow-up principles.

Severe neurotoxicity after brexucabtagene autoleucel is common, associated with MRI/EEG changes and longer hospitalization, but importantly does not negatively impact treatment response or survival in MCL patients.

Combining time-limited ibrutinib with CTL019 CAR-T in relapsed/refractory MCL achieved an 80% CR rate with manageable toxicity, showing efficacy even in BTKi-pretreated and TP53-mutated patients.

Single-cell analysis reveals the HSP90-MYC-CDK9 network drives sequential BTKi and CAR-T resistance, suggesting co-targeting HSP90 and CDK9 as a novel strategy for dual-refractory MCL.

This workshop report summarizes recent advances in MCL biology and treatment, including BTKi and CAR-T, and outlines key research priorities to overcome resistance and clinical heterogeneity for future progress.

Radiation therapy is a feasible bridging strategy to control disease in relapsed/refractory MCL patients awaiting CAR-T infusion, potentially improving eligibility and outcomes for those with bulky disease.

This indirect comparison of ZUMA-2 (brexucabtagene autoleucel) and SCHOLAR-2 (standard of care) demonstrates a substantial overall survival benefit for CAR-T therapy in relapsed/refractory MCL after BTKi failure.

This review synthesizes MCL's genomic heterogeneity with the evolving therapeutic landscape, focusing on novel agents like BTKi and CAR-T and strategies for overcoming resistance in relapsed/refractory disease.

This paper outlines strategies for improved collaboration between community oncologists and authorized centers to overcome logistical and educational barriers, ensuring timely referral and access to CAR-T therapy for MCL.

This systematic review of real-world data supports positioning covalent BTKis as second-line therapy for relapsed/refractory MCL, followed by CAR-T cells for patients relapsing after BTKi treatment.

This review details the pathophysiology and management of CAR-T toxicities like CRS and ICANS, providing essential guidance for clinicians treating relapsed/refractory MCL patients with this therapy.

This review consolidates efficacy and toxicity data for FDA-approved CAR-T products in aggressive B-cell lymphomas, including MCL, serving as a practical guide for this established relapsed/refractory treatment.

This meta-analysis of 984 R/R MCL patients confirms high CAR-T efficacy (74% CR, 69% 1-year OS), providing robust, pooled outcome data for this heavily pretreated population.

This review summarizes the evolving Japanese MCL treatment landscape, highlighting novel therapies like BTKi, BCL2i, and CAR-T to address resistance in high-risk subsets like TP53-mutated and blastoid.

This case report identifies therapy-related acute myeloid leukemia as a serious long-term toxicity after brexucabtagene autoleucel, highlighting the need for post-CAR-T surveillance for secondary malignancies.

This study shows ROR1 is heterogeneously expressed in 44% of MCL tumors, indicating that patient selection will be critical for developing ROR1-targeted therapies like ADCs or CAR-T.

In a real-world cohort including MCL, the Hematotox-Score predicted early cytopenias post-CAR-T but not survival, underscoring the need for improved prognostic tools for toxicity management.